Abstract. Neuroblastoma is the second most common extracranial malignant solid tumor that occurs in childhood, and metastasis is one of the major causes of death in neuroblastoma patients. The epithelial-mesenchymal transition (EMT) is an important mechanism for both the initiation of tumor invasion and subsequent metastasis. Therefore, this study investigated the mechanism by which transforming growth factor (TGF)-β1 induces EMT in human neuroblastoma cells. Using quantitative RT-qPCR and western blot analyses, we found that the mRNA and protein expression levels of E-cadherin were significantly decreased, whereas that of α-SMA was significantly increased after neuroblastoma cells were treated with different concentrations of TGF-β1. A scratch test and Transwell migration assay revealed that cell migration significantly and directly correlated with the concentration of TGF-β1 indicating that TGF-β1 induced EMT in neuroblastoma cells and led to their migration. Inhibiting Smad2/3 expression did not affect the expression of the key molecules involved in EMT. Further investigation found that the expression of the glioblastoma transcription factor (Gli) significantly increased in TGF-β1-stimulated neuroblastoma cells undergoing EMT, accordingly, interfering with Gli1/2 expression inhibited TGF-β1-induced EMT in neuroblastoma cells. GANT61, which is a targeted inhibitor of Gli1 and Gli2, decreased cell viability and promoted cell apoptosis. Thus, TGF-β1 induced EMT in neuroblastoma cells to increase their migration. Specifically, EMT induced by TGF-β1 in neuroblastoma cells did not depend on the Smad signaling pathway, and the transcription factor Gli participated in TGF-β1-induced EMT independent of Smad signaling.
Introduction
Neuroblastoma is the second most common extracranial malignant tumor that occurs in childhood (1) . It is a high-grade malignancy, and metastasis often occurs in the early phase of disease (2) . Therefore, the long-term outcome of children with neuroblastoma who are classified as high-risk patients remains as poor as 30%, despite the administration of aggressive multimodal therapy, and metastasis is one of the major causes of death in patients with neuroblastoma (3, 4) . Tumor metastasis has been shown to be associated with the epithelial-mesenchymal transition (EMT), which promotes the loss of tight junctions between cancer cells, increases metastasis and invasion of cancer cells, and inhibits apoptosis (5, 6) . However, the mechanisms regulating EMT in tumor cells are complex and involve the cell microenvironment and various cytokine signal transduction pathways. Transforming growth factor (TGF)-β level was indeed elevated in neuroblastoma cases and found to be related to a pathway important for promoting neuroblastoma invasion (7, 8) and may be a potential treatment target in neuroblastoma (9) . Although, TGF-β1 is known to induce EMT (10) , the mechanism of this induction in neuroblastoma is poorly understood.
The glioblastoma transcription factor (Gli) plays an important role in humans by regulating the growth and differentiation of normal cells, and it also plays an important role in the initiation and development of various tumors (11, 12) . This study focused on the regulatory effects of TGF-β1 on EMT in human neuroblastoma cells and the correlation of these effects with transcription factor Gli.
Materials and methods
Cell culture. Human neuroblastoma SK-N-SH, SH-SY5Y, IMR-32 cells were purchased from the Shanghai Institute of Biochemistry and Cell Biology of the Chinese Academy of Sciences. SK-N-SH cells were established from the brain metastases of a patient with prostate cancer who had a 3-year history of neuroblastoma. These cells exhibited irregular shapes, including spindle, round, and polygonal shapes. SH-SY5Y cells were established from the bone marrow metastases of a patient with neuroblastoma. The cells grow as clusters of neuroblastic cells with multiple, short, fine cell processes (neurites). Cells will aggregate, form clumps and
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float. The IMR-32 cells were established from an abdominal mass occurring in a 13-month-old Caucasian male. The cells were cultured in DMEM medium containing 100 ml/l FBS and incubated in a 37˚C incubator containing 5% CO 2 . Morphology. The cells were seeded in 6-well plates and treated with TGF-β1 for 14 days. The changes in cell morphology were observed daily by phase contrast microscopy, and the cells were also imaged.
Immunofluorescence staining. The cells were cultured in 24-well plates that were pre-loaded with a small round slide in each well. When the cells attached to the slides, the slides were removed and fixed in 4% paraformaldehyde at room temperature for 30 min. Primary antibodies were then added, and the cells were incubated at room temperature for 2 h before being incubated with FITC-labeled secondary antibodies in the dark. The slides were then stained with DAPI, washed twice with PBS, mounted, and observed and imaged under a fluorescence microscope.
Total RNA extraction and reverse transcription. The cells were grown in 25 cm 2 cell culture flasks until they reached 80% confluence, at which point 1 ml of TRIzol was added. The suspension was added to a 1.5-ml centrifuge tube, and 200 µl of chloroform was added. The top layer, which consisted of a colorless liquid, was retained, and an equal volume of isopropanol was added, followed by centrifugation. The supernatant was discarded, the white pellet at the bottom was precipitated twice with 75% ethanol, and the supernatant was discarded after centrifugation. After drying, the pellet was dissolved in DEPC water, the RNA concentration was measured, and reverse transcription was performed according to the manufacturer's instructions.
Fluorescent reverse transcription quantitative polymerase chain reaction (RT-qPCR).
The cells were cultured, RNA was extracted using the TRIzol method, and 500 µg RNA was reverse transcribed into cDNA, which was diluted 5-fold to detect changes in gene expression by RT-qPCR. The total reaction volume was 20 µl and consisted of 10 µl of SYBR Premix Ex Taq™, 2 µl of cDNA, 6 µl of DEPC water, and 1 µl each of the upstream and downstream primers. RT-qPCR was performed using the following primers: E-cadherin: 5'-GGA TGTGAATGAAGCCCCCA-3' (sense) and 5'-CCTGGGCAGT GTAGGATGTG-3' (antisense). β-actin: 5'-GCACTCTTCCA GCCTTCCTT-3' (sense) and 5'-AATGCCAGGGTACATG GTGG-3' (antisense). α-SMA: 5'-CCCTTGAGAAGAGTTA CGAGTTG-3' (sense) and 5'-ATGATGCTGTTGTAGGT GGTTTC-3' (antisense). Gli1: 5'-GAGCCAGAAGTTGGGA CCTC-3' (sense) and 5'-CCTCGCTCCATAAGGCTCAG-3' (antisense). Gli2: 5'-GGTGAGTCGTCCAGCCAAAT-3' (sense) and 5'-ACTGTCAAGGGGGAAGCAGA-3' (antisense). Smad2: 5'-GCCCTAAAGTGCCTGGGATT-3' (sense) and 5'-TGGAG AATCGCTTTTGGGCA-3' (antisense). Smad3: 5'-TACCAGC AGCAAGAGAGTGC-3' (sense) and 5'-CTGAAAGGGGCCT ACAAGGG-3' (antisense).
The PCR procedure was performed on the Roche RT-PCR facility (Roche Light Cycle) described below: initial steps at 95˚C for 3 min, then each of 40 cycles: denaturation for 7 sec at 95˚C annealing for 10 sec at 55˚C, extending for 15 sec at 72˚C. First, ∆Ct = Ct Gene -Ct β-actin. Then, ∆∆Ct = ∆Ct sample 2 -∆Ct sample 1. Lastly, 2 -∆∆Ct was calculated to represent the relative mRNA expression of target genes. β-actin was used as an inner control.
Western blot analysis. After the culture medium was aspirated, each 10-cm dish was washed with PBS, and protein lysis buffer was added (containing protease and phosphatase inhibitors) to extract the proteins. The proteins were separated by 10% polyacrylamide gel electrophoresis, transferred to a polyvinylidene fluoride (PVDF) membrane (the PVDF membrane was activated by methanol), and blocked with 5% skim milk. Primary antibodies were then added, followed by overnight incubation in a rotator at 4˚C and subsequent hybridization with secondary antibodies. Enhanced chemiluminescence (ECL) detection was used to detect the protein bands.
Scratch test.
The backs of the 6-well plates were labeled with horizontal lines using marker pens. After digestion, the cells were seeded in 6-well plates, allowed to adhere, and treated with TGF-β1. After the cells covered the entire bottom of the plate, scratches were made by perpendicularly scratching the bottom of the wells with a 200-µl pipette tip. The cell culture medium was aspirated, serum-free medium was added, and the plates were removed and imaged once every 4-6 h.
Transwell migration assay. The migration ability of SK-N-SH cells was measured using BD Falcon cell culture inserts containing 8-µm pore size PET membranes and 24-well BD BioCoat Matrigel Invasion Chambers (BD Biosciences, Bedford, MA, USA). SK-N-SH cell suspensions were adjusted to contain 1x10 5 cells and added to the upper chamber in serum-free medium treated with TGF-β1 (5 ng/ml). Complete medium was added to the bottom wells of the chambers. After incubation at 37˚C under 5% CO 2 for 72 h, cells that had not migrated were removed from the upper face of the filters using cotton swabs, and the cells that had migrated were fixed and stained with crystal violet solution. Cell viability assay. Cell viability and cytotoxicity was assessed by cell counting kit-8 (CCK8). Cells were seeded in 96-well plates at density of 5,000 cells in 100 µl medium per well. After being treated with various concentration of GANT61 for 48 h at 37˚C, CCK8 was added to each well and the cells were incubated for a further 2 h at 37˚C, after which absorbance was measured using a microplate reader with a test wavelength of 450 nm. Data were analyzed from three independent experiments.
Flow cytometry analysis. To analyze apoptosis, cells were digested with trypsin and washed with PBS. Apoptotic detection kit was from BD (BD Biosciences). BD Pharmingen-FITC Annexin V Apoptosis Detection kit cat. no. 556547) was used and staining was conducted according to the kit instructions. The cells was analyzed by BD FACSCalibur flow cytometry facility. Annexin V-FITC + /PI -represented the apoptotic cell population.
Statistical analysis. All statistical analyses were performed using GraphPad Prism 5 software (GraphPad Software, Inc., La Jolla, CA, USA). Measured data are expressed as the means ± standard deviation. Comparisons of the means of multiple groups were conducted using a one-way analysis of variance (ANOVA). Comparisons of the means of two groups were conducted using a t-test. A value of P<0.05 was considered statistically significant.
Results
Changes in cell morphology and the occurrence of EMT after treatment with TGF-β1. SK-N-SH cells exhibited irregular shapes, including spindle, round, and polygonal shapes. Immunofluorescence staining showed that SK-N-SH cells expressed TGF-β receptor I and II. After three days of treatment with different concentrations of TGF-β1, some spindle-shaped cells showed elongated cell bodies with a more pronounced spindle-shaped appearance. After 14 days of treatment with TGF-β1 (10 ng/ml), the spindle-shaped cells showed elongated cell bodies and had a more pronounced spindle-shaped appearance, and most cells were spindle-shaped, suggesting the occurrence of EMT (Fig. 1A) . Immunofluorescence staining showed that SK-N-SH cells expressed the EMT markers E-cadherin and α-SMA in the cytoplasm (Fig. 1B) . After SK-N-SH cells were treated with TGF-β1 (0, 1, 5 and 10 ng/ml) for three days, quantitative densitometric analysis showed that the protein expression level of the epithelial cell marker E-cadherin was significantly decreased (F=74.81, P=0.0006), whereas that of α-SMA was significantly increased (F=68.81, P=0.0007) (Fig. 1C) . The mRNA expression level of E-cadherin was significantly decreased (F=8.144, P=0.0353), whereas that of α-SMA was significantly increased (F=547.3, P<0.0001). These changes, which occurred simultaneously, suggested that the cells had undergone EMT.
TGF-β1 promotes migration in SK-N-SH cells after treatment with TGF-β1.
The migration ability of SK-N-SH cells after treatment with 5 ng/ml TGF-β1 for 72 h, as analyzed with a Transwell migration assay, were higher than those of the SK-N-SH control group (t=16.07, P=0.0396) (Fig. 2A) . SK-N-SH cells were treated with TGF-β1 (0, 1, 5 and 10 ng/ml) for 72 h, and the medium was then exchanged for serum-free medium. The cells were imaged once every 4 h, and the results showed that the TGF-β1 concentration significantly and directly correlated with cell migration (Fig. 2B) . These results indicated that TGF-β1 plays a role in neuroblastoma cell migration.
Interfering with the expression of Smad2/3 does not affect the expression of key EMT molecules. SK-N-SH cells were transfected with SiRNA against Smad2/3 and treated with TGF-β1 for 72 h, and these cells expressed significantly less Smad2 and Smad3 protein than the control group (t=34.61, P=0.0008; t=11.73, P=0.0072) (Fig. 3A and B) . The mRNA expression levels of Smad2 and Smad3 were also significantly lower than those of the control group (t=12.88, P=0.0493; t=12.94, P=0.0491). Thus, Smad2 and Smad3 expression was successfully knocked down.
After treatment with TGF-β1 (5 ng/ml), the expression of the epithelial cell marker E-cadherin remained significantly lower in the Smad2/3 SiRNA group than the control group (t=6.299, P=0.0243), whereas the expression of α-SMA decreased slightly in the Smad2/3 SiRNA group, but this difference was not significant compared to the control group (t=1.502, P=0.271) (Fig. 3C) . Thus, knockdown of the expression of Smad2 and Smad3 did not affect the expression of key EMT molecules induced by TGF-β1 in SK-N-SH cells.
TGF-β1 significantly increases Gli expression in neuroblastoma cell lines undergoing EMT.
Consistent with immunofluorescence staining results, we observed SK-N-SH human neuroblastoma cells expressed the transcription factors Gli1, Gli2 and Gli3, respectively (Fig. 4A) . Accordingly, western blot analysis confirmed that the protein expression levels of the transcription factors Gli1, Gli2 and Gli3 were significantly increased after TGF-β1 treatment for 3 days in SK-N-SH cells (F=268.3, P<0.0001; F=36.06, P=0.0024; F=17.17, P=0.0095). It has been reported that Gli1 and Gli2 are more closely related to EMT in cancer (11,13), we aslo found the ptotein expression of Gli1/2 increased after TGF-β1 treatment for 3 days in SH-SY5Y (F=68.45, P=0.0007; F=36.81, P=0.0023) and IMR-32 cells (F=31.67, P=0.003; F=18.24, P=0.0085) (Fig. 4B) . After SK-N-SH cells were transfected with Smad2 and Smad3 plasmid and treated with TGF-β1 for 72 h, western blot analysis showed that the protein expression levels of Smad2 and Smad3 were significantly higher in the transfection group (t=19.11, P=0.0027; t=20.41, P=0.0024) ( Fig. 4C) . Therefore, plasmid transfection to overexpress Smad2/3 was successful. Western blot analysis also showed that the protein expression of the transcription factor Gli2 did not significantly differ after SK-N-SH cells were transfected with Smad2 and Smad3 plasmid or SiRNA Smad2/3 and treated with TGF-β1 for 72 h (F=1.643, P=0.3297; t=2.614, P=0.0602) (Fig. 4D) , indicating that the increase in Gli2 expression after treatment with TGF-β1 was not related to Smad2 or Smad3 overexpression or knockdown.
Interfering with the expression of Gli1/Gli2 inhibits TGF-β1-induced EMT in SK-N-SH cells.
GANT61, a small-molecule inhibitor of Hedgehog signaling effector Gli protein, was reported to have a cytotoxic effect on neuroblastoma cell lines (14) . After SK-N-SH cells were treated with different concentrations (0, 1, 10 and 20 µmol/l) of GANT61 for 72 h, RT-qPCR showed that Gli1 and Gli2 mRNA expression were decreased compared to the control group (F=42.29, P=0.0017; F=701.6, P<0.0001) (Fig. 5A and B) . It was found that the inhibition of Gli2 was more obvious than Gli1, so Gli2 was used as the main research object in the subsequent experiments. Western blot analysis showed that the protein expression levels of the transcription factors Gli2 were decreased by GANT61 compared to the control group (F=42.24, P=0.0017) (Fig. 5C) . SK-N-SH cells were treated with GANT61 (5 µmol/l) for 72 h, followed by treatment with different concentrations of TGF-β1 for 72 h. Western blot analysis showed that the expression levels of E-cadherin and α-SMA were significantly increased (F=93.93, P=0.0004; F=40.50, P=0.0019) (Fig. 5D ), indicating that inhibiting the expression of Gli1/2 interfered with the expression of E-cadherin, a key regulator of EMT.
Transfecting SK-N-SH cells with SiRNA against Gli1 and Gli2 for 72 h significantly knocked down the protein expression levels of Gli1 and Gli2 compared with the control group (P=0.043, 0.018) (Fig. 5E ). The protein expression of E-cadherin failed to decrease after transfection with SiRNA against Gli1 or Gli2 and subsequent treatment with TGF-β1 for 72 h. In fact, the expression of E-cadherin significantly increased in cells co-transfected with SiRNA against Gli1 and Gli2 compared with the control group (F=87.80, P=0.0004). The protein expression of α-SMA was decreased, but this decrease was not significant (F=6.386, P= 0.0526) (Fig. 5E  and F) . Thus, inhibiting Gli1/Gli2 expression inhibited TGF-β1-induced EMT in SK-N-SH cells.
GANT61 decreases cell viability and promotes apoptosis in neuroblastoma cells.
Using CCK8 assay, we evaluated the viability of SK-N-SH and SH-SY5Y cells under various concentrations of GANT61 (0-20 µmol/l). Treating neuroblastoma cells with GANT61 for 72 h significantly reduced the number of cells, as observed by microscopy (Fig. 6A) . The low concentration of GANT61 did not affect cell viability obviously, while the higher concentration of GANT61 significantly reduced the number of neuroblastoma cells. SH-SY5Y cells had a fewer viable cells at high cencentration of GNAT61, with 26.9% live cells at 20 µmol/l GANT61, whereas SK-N-SH cells had 43.34% live cells under the same concentration of GANT61.
We used Annexin V-FITC/PI double staining to evaluate apoptotic status of neuroblastoma cells after GANT61 treatment. Indeed, flow cytometry showed the number of apoptotic cells increased with the concentration of GANT61 in both neuroblastoma cell lines (P<0.05) (Fig. 6B) 
Discussion
Metastasis is an important step in cancer progression and an important cause of death in patients with malignant tumors. A variety of regulatory mechanisms are involved in tumor metastasis, and one of the most important mechanisms that promotes tumor cell metastasis is EMT (15, 16) . During EMT, specific cytokines transform cells from an epithelial to a mesenchymal phenotype. EMT is required for normal embryonic development, but this process can also trigger certain disease processes, including tissue fibrosis, tumor formation, and tumor cell migration (17) . EMT generally does not occur in normal adult cells, but EMT can be activated by external stimuli or internal signaling factors. Although EMT is known to be the first step of cell migration, the role of EMT in the spread of cancer cells has not received significant attention until recently (18) . After EMT, cell adhesion is weakened, whereas cell migration characteristics are enhanced. During tumorigenesis, normal epithelial cells undergo EMT and subsequently develop into primary cancer. The cancer cells then continue to progress and spread locally via EMT before invading the lymphatic and blood vessels to ultimately metastasize. During this process, both cell phenotypes and cell markers change (19) ; specifically, the expression of epithelial markers, such as E-cadherin, is reduced, whereas that of mesenchymal markers, such as vimentin, N-cadherin, and α-SMA, is increased. TGF-β, an important member of the TGF-β family, has received increasing attention as a major inducer of EMT (20) (21) (22) that participates in tumor initiation and progression as well as the development of fibrotic diseases (23) (24) (25) . In recent years, TGF-β1 has been identified in a variety of tumors in which EMT is closely related to primary infiltration and secondary metastasis, such as colon, liver, and breast cancer (26) , and limited studies of neuroblastoma have been performed in children.
In this study, three days of treatment with TGF-β1 transformed the originally spindle-shaped cells into cells with elongated cell bodies that had a more pronounced spindle-shaped appearance, whereas cells exhibited other shapes did not show significant changes. Furthermore, most cells were spindle-shaped after 14 days of TGF-β1 treatment, i.e., most cells exhibited a mesenchymal phenotype, which suggested that EMT had occurred. To further confirm that EMT had occurred in neuroblastoma cells, we used western blot analysis to examine the expression of EMT-related marker proteins. The results showed that the epithelial cell marker E-cadherin was downregulated, and the expression of the mesenchymal cell marker α-SMA was increased. These results were confirmed by RT-qPCR, which suggested that the tumor cells had undergone EMT. Because EMT can increase the metastasis and invasion of cancer cells, scratch and Transwell migration assays were used to show that the migration of cells significantly increased after treatment with TGF-β1. Therefore, EMT enhanced the migration of neuroblastoma cells.
The signaling pathways by which TGF-β1 induces EMT in neuroblastoma cells remain unknown. TGF-β signaling pathways mainly include two types of signal transduction pathways: Smad-dependent pathways and Smad-independent pathways (21). Smad2 and Smad3 are receptor-regulated proteins and are the key proteins in Smad-dependent signaling. Accordingly, neuroblastoma cells were transfected with SiRNA against Smad2/3, but TGF-β1 treatment continued to decrease E-cadherin expression in these cells. Thus, the Smad signaling pathway was not directly involved in TGF-β1-induced EMT in neuroblastoma cells, suggesting that this process is mediated by Smad-independent signaling.
An increasing body of evidence has shown that Smadindependent pathways, such as p38, JNK-MAPK, PI3K-AKT-mTOR, and others, are of great significance in cancer development because they regulate cell survival, proliferation, migration, invasion and EMT (27) (28) (29) (30) (31) . Recently, many studies have shown that TGF-β1 induces EMT in lung (32) and breast (33) cancer and that this process relies on the Sonic-Hedgehog-Gli (SHH) signaling pathway.
The SHH signaling pathway was originally found to play an extremely important role in embryonic neural crest development, and recently, it was found to be associated with tumor initiation, progression, and invasion (11, 34, 35) . SHH binds to the Patched-1 (Ptch1) transmembrane receptor and then activates its downstream receptor Smoothened (Smo), which results in a signaling cascade that includes the downstream activation of Gli1 and Gli2 and the downregulation of Gli3 expression.
Yue et al reported that SHH pathway components were aberrantly expressed in lung cancer tissue. Specifically, Gli1 expression was inversely associated with the expression of the EMT markers E-cadherin and β-catenin in lung cancer specimens (36) . Moreover, the excessive activation of the SHH signaling pathway was directly related to the nervous system and other cancers (37, 38) . Souzaki et al found that most patients with neuroblastoma who did not exhibit v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN) amplification were positive for Shh, Gli1, and Ptch1. In cases without MYCN amplification, the high expression of Gli1 was significantly associated with early clinical stage and a good prognosis of the patients. Furthermore, the activation of the SHH signaling pathway in neuroblastoma may be associated with the differentiation of neuroblastoma (39) .
In this study, immunofluorescence staining detected Gli1, Gli2 and Gli3 protein expression in SK-N-SH cells, suggesting that the SHH signaling pathway was activated in neuroblastoma cells. After TGF-β1 induced EMT in neuroblastoma cells, western blots showed that the protein expression levels of Gli1, Gli2 and Gli3 were significantly increased compared to the control group, suggesting that the SHH signaling pathway can be further activated after EMT in neuroblastoma cells. TGF-β1 treatment increased Gli2 expression, irrespective of Smad2/Smad3 overexpression or knocked down, indicating that Smad2 or Smad3 was not related to the expression of Gli2.
Treating neuroblastoma cells with GANT61, a small-molecule inhibitor of Gli1/2, cell viability was decreased and apoptosis was increased, which indicated that Gli1/2 inhibition decreased tumor cell viability and promoted their apoptosis. Therefore, Gli1/2 may be a potential target for the treatment of neuroblastoma.
Inhibiting Gli1/2 expression by SiRNA or GANT61 in neuroblastoma cells attenuated TGF-β1-mediated decreasing in E-cadherin. Inhibiting Gli1/2 affected the expression of key EMT molecules, suggesting that transcription factor Gli was involved in TGF-β1-mediated EMT in neuroblastoma cells. Moreover, the inhibition of the transcription factor Gli may reduce the malignant behavior of neuroblastoma cells, and the SHH signaling pathway may be a key target for the treatment of neuroblastoma. The knockdown of the Gli1/2 gene reportedly inhibited the expression of key EMT regulatory proteins in human trophoblasts and skin tumors (13, 40) . We confirmed that TGF-β1 increased Gli expression, and Gli was related to the occurrence of EMT in neuroblastoma cells. The molecular mechanism by which Gli affected EMT appeared not to be directly related to Smad, but this mechanism requires further study.
